Nippon India Pharma Fund Direct-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
NAV: ₹631.76+0.34%
10 Jul 2026
Holdings Analysis
Equity, debt and cash allocation snapshot with market cap distribution for Nippon India Pharma Fund Direct-Growth.
Market Cap Distribution
Large Cap (30.4%)
Mid Cap (41.6%)
Small Cap (28.0%)
Historical Asset Allocation
| Asset | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Equity | 97.64% | 97.98% | 98.70% | 99.45% | 99.68% | 98.96% |
| Debt | 0.01% | 0.00% | 0.01% | 0.01% | 0.00% | 0.00% |
| Others (incl. cash) | 2.35% | 2.02% | 1.29% | 0.54% | 0.32% | 1.04% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
36
P/E Ratio
38.70
P/B Ratio
5.55
Top Holding %
12.78%
Top 5 Holdings %
38.52%
Top 10 Holdings %
58.09%
AUM
₹9,044 Cr
Expense Ratio
1.00%
Since Inception
17.68%
Max Drawdown
-0.24%
Alpha
-0.73%
Sharpe Ratio
1.00
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 62,06,349 | 1,155.93 | 12.78% | -0.57%↓ |
| Lupin Ltd. | Healthcare | 27,83,991 | 673.45 | 7.45% | 0.14%↑ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 44,49,746 | 603.88 | 6.68% | -0.04%↓ |
| Cipla Ltd. | Healthcare | 37,95,054 | 556.13 | 6.15% | -0.01%↓ |
| Divis Laboratories Ltd. | Healthcare | 7,50,754 | 493.92 | 5.46% | -0.34%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 5,48,795 | 476.46 | 5.27% | 0.07%↑ |
| Mankind Pharma Ltd. | Healthcare | 14,31,195 | 364.33 | 4.03% | 0.09%↑ |
| Sai Life Sciences Ltd. | Healthcare | 25,55,745 | 315.46 | 3.49% | 0.06%↑ |
| Ajanta Pharma Ltd. | Healthcare | 9,13,918 | 312.81 | 3.46% | 0.25%↑ |
| Max Healthcare Institute Ltd. | Healthcare | 26,58,082 | 300.16 | 3.32% | 0.35%↑ |
| Medplus Health Services Ltd. | Healthcare | 35,45,229 | 287.43 | 3.18% | -0.50%↓ |
| Vijaya Diagnostic Centre Ltd. | Healthcare | 18,71,618 | 253.16 | 2.80% | -0.41%↓ |
| Thyrocare Technologies Ltd. | Healthcare | 43,66,909 | 239.87 | 2.65% | 0.09%↑ |
| Ipca Laboratories Ltd. | Healthcare | 13,64,742 | 232.14 | 2.57% | 0.16%↑ |
| Glaxosmithkline Pharmaceuticals Ltd. | Healthcare | 9,13,226 | 223.77 | 2.47% | 0.13%↑ |
| Gland Pharma Ltd. | Healthcare | 8,00,549 | 199.74 | 2.21% | 0.12%↑ |
| Abbott India Ltd. | Healthcare | 74,339 | 189.12 | 2.09% | -0.22%↓ |
| Alkem Laboratories Ltd. | Healthcare | 3,23,678 | 180.29 | 1.99% | -0.07%↓ |
| Dr. Lal Pathlabs Ltd. | Healthcare | 10,18,224 | 167.62 | 1.85% | -0.05%↓ |
| Narayana Hrudayalaya Ltd. | Healthcare | 8,23,911 | 162.45 | 1.80% | -0.01%↓ |
1 / 2
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 97.64% | 97.98% | 98.70% | 99.45% | 99.68% | 98.96% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
30.7 / 100
Weighted average Value score is 30.7. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
78.2 / 100
Weighted average Price Momentum score is 78.2. This indicates that portfolio has high momentum using composite of momentum measures.
Quality score
89.6 / 100
Weighted average Quality score is 89.6. This indicates that portfolio has high quality using composite of quality measures.
QVM score
79.3 / 100
Weighted average QVM score is 79.3. This indicates that portfolio has high QVM score and hence could be considered for investment.
Red Flags
Frequently Asked Questions
What are the top holdings of Nippon India Pharma Fund Direct-Growth?
The top holdings of Nippon India Pharma Fund Direct-Growth sorted by portfolio weight are listed in the Top Portfolio Holdings section of the Holdings tab.
How many stocks does Nippon India Pharma Fund Direct-Growth hold in its portfolio?
Nippon India Pharma Fund Direct-Growth holds 36 securities in its portfolio. The top 5 holdings account for 38.52% of the portfolio and the top 10 for 58.09%.
What is the sector allocation of Nippon India Pharma Fund Direct-Growth?
The sector allocation of Nippon India Pharma Fund Direct-Growth is in the Sector Allocation section, showing each industry's weight in the portfolio.
What is the equity and debt allocation of Nippon India Pharma Fund Direct-Growth?
As of 30 Jun 2026, Nippon India Pharma Fund Direct-Growth has 97.64% in equity, 0.01% in debt and 2.35% in cash/others. This asset mix determines the fund's overall risk-return profile.
What is the market cap allocation of Nippon India Pharma Fund Direct-Growth?
Nippon India Pharma Fund Direct-Growth's equity portfolio — Large Cap: 30.38%, Mid Cap: 41.59%, Small Cap: 28.03%. Market cap allocation determines the fund's risk profile — large cap offers stability while mid and small cap offer higher growth potential with higher volatility.
Is Nippon India Pharma Fund Direct-Growth a concentrated or diversified fund?
Nippon India Pharma Fund Direct-Growth holds 36 securities, with the top 10 accounting for 58.09% of the portfolio and the top 5 for 38.52%. This is a moderately diversified fund balancing conviction positions with risk spread.
What is the credit quality of Nippon India Pharma Fund Direct-Growth?
The credit quality breakdown of Nippon India Pharma Fund Direct-Growth's debt portfolio is in the Credit Rating section. For equity-oriented funds, this section may not be applicable.
How often does Nippon India Pharma Fund Direct-Growth change its portfolio?
The portfolio currently holds 36 securities with the top 10 accounting for 58.09% as of 30 Jun 2026. Portfolio turnover reflects how actively the fund manager trades. A high turnover increases transaction costs while a low turnover reflects a buy-and-hold approach. Historical asset allocation snapshots across multiple dates are in the Holdings Analysis section.
What is the PE ratio of Nippon India Pharma Fund Direct-Growth's portfolio?
The weighted average PE ratio of Nippon India Pharma Fund Direct-Growth's portfolio is 38.70 and the PB ratio is 5.55. These metrics reflect the overall valuation and interest rate sensitivity of the portfolio.
When is the latest portfolio disclosure for Nippon India Pharma Fund Direct-Growth?
The latest portfolio disclosure for Nippon India Pharma Fund Direct-Growth is as of 30 Jun 2026. Mutual funds and ETFs in India are required to disclose their full portfolio monthly, within 10 business days of month-end. You can switch between historical disclosure dates using the date selector in the Top Portfolio Holdings section.